• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. EUFLEXXA 1% SODIUM HYALURONATE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. EUFLEXXA 1% SODIUM HYALURONATE Back to Search Results
Catalog Number 6301182010
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Inflammation (1932); Pain (1994); Unspecified Kidney or Urinary Problem (4503); Appropriate Clinical Signs, Symptoms, Conditions Term / Code Not Available (4581)
Event Date 01/01/2021
Event Type  Injury  
Event Description
Bladder inflammation, pressure [cystitis noninfective]. Kidney inflammation, pressure [urinary tract inflammation]. Hip replacement [hip arthroplasty]. Required hospitalization to relieve pressure and stones [nephrolithiasis]. Chronic regional pain syndrome [pain]. Case (b)(6) is a serious spontaneous case received from a non health professional via a regulatory authority in united states. This report concerns a patient (no patient identifiers provided) who experienced bladder inflammation/pressure, kidney inflammation/pressure, hip replacement, required hospitalization to relieve pressure and stones and chronic regional pain syndrome during treatment with intra-articular euflexxa (sodium hyaluronate) solution for injection unknown dose and frequency, used for unknown indication from an unknown start date to an unknown stop date and co-suspect drug covid-19 vaccine mrna (pfizer), 2 doses, for immunisation from an unknown start date to an unknown stop date. The consumer reported that the patient had a second hip replacement, was diagnosed with chronic regional pain syndrome (crps), had bladder and kidney inflammation after both covid-19 vaccines (pfizer) and first required hospitalization to relieve pressure and stones. No further information was provided. The patient was hospitalized on an unknown date due to bladder inflammation/pressure. The patient was hospitalized on an unknown date due to kidney inflammation/pressure. The patient was hospitalized on an unknown date due to hip replacement. The patient was hospitalized on an unknown date due to required hospitalization to relieve pressure and stones. Action taken with euflexxa was unknown. Action taken with covid-19 vaccine mrna was unknown. At the time of reporting, the outcome of bladder inflammation/pressure was unknown, the outcome of kidney inflammation/pressure was unknown, the outcome of hip replacement was unknown, the outcome of required hospitalization to relieve pressure and stones was unknown, the outcome of chronic regional pain syndrome was unknown. The patient's med hist/procedure was significant for hip replacement (from unknown start date to unknown stop date). No concomitant medication was reported. The events bladder inflammation, pressure, kidney inflammation, pressure, hip replacement, required hospitalization to relieve pressure and stones were reported as serious. The event chronic regional pain syndrome was reported as non-serious. At the time of reporting the case outcome was unknown. Sender comment: due to clinical interpretation in alignment with known safety profile, company causality is considered not related to euflexxa for the 'bladder inflammation/pressure', 'kidney inflammation/pressure' and 'hip replacement' events as there is no clinical evidence, furthermore, it was reported that the bladder and kidney inflammation developed after covid vaccine, and the crps after the hip replacement. Overall listedness (core label) is unlisted. Reporter causality: not related. Company causality: not related. Other case numbers: internal # - others
=
mw5105059. This ae occurred in united states and concerns the medical device euflexxa. Please report to your local health authority if required by local law. This ae is not reportable in eu because it does not meet the definition of a medical device incident according to the requirements of the medical device directive/ because it did not occur in a eu + efta country and did not result in a corrective action by the manufacturer. No corrective action was done by the manufacturer or requested by regulators.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NameEUFLEXXA
Type of Device1% SODIUM HYALURONATE
Manufacturer (Section D)
BIO-TECHNOLOGY GENERAL (ISRAEL) LTD.
be'er tuvia industrial zone
pob 571
kiryat malachi, 83104
IS 83104
Manufacturer (Section G)
BIO-TECHNOLOGY GENERAL (ISRAEL) LTD.
be'er tuvia industrial zone
pob 571
kiryat malachi, 83104
IS 83104
Manufacturer Contact
100 interpace parkway
parsippany, NJ 07054
9737961600
MDR Report Key12868221
MDR Text Key281272898
Report Number3000164186-2021-00050
Device Sequence Number1
Product Code MOZ
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P010029
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Other
Reporter Occupation
Type of Report Initial
Report Date 11/24/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/24/2021
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Catalogue Number6301182010
Was Device Available for Evaluation? No
Date Manufacturer Received11/09/2021
Was Device Evaluated by Manufacturer? No Answer Provided
Is the Device Single Use? Yes

Patient Treatment Data
Date Received: 11/24/2021 Patient Sequence Number: 1
-
-